Top

Published in:

01-09-2019 | Thalassemia | Original Article

Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator

Authors: Seyed Kamal Eshagh Hossaini, Mohammad reza Haeri

Published in: Journal of Hematopathology | Issue 3/2019

Abstract

Patients with beta-thalassemia suffer from iron overload, and hepcidin, as the main regulator of iron hemostasis, can indicate iron overload better than serum ferritin, but changes in serum hepcidin levels are affected by the type of thalassemia (major or intermediate) and by type of treatments. The present study aimed to determine the correlation between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia under chelation therapy. This cohort study investigated 143 patients with thalassemia (122 patients with thalassemia major and 21 patients with and thalassemia intermedia) who referred to Thalassemia Center of Qom University of Medical Sciences, Qom, Iran. The serum level of ferritin was measured twice in all patients: in the beginning and after taking iron chelator by ECL method. Hepcidin was assayed at the end of the study by ELISA methods. Demographic data and clinical history of the patients (type of disease, type of drugs used, and blood transfusion history) were completely recorded. The mean serum level of hepcidin in the TM group (2249.62 ± 1547.37 ng/ml) was greater than the TI group (1482.43 ± 1314.26 ng/ml) (p = 0.007). However, there was no meaningful difference in serum ferritin level between the two groups (2997.74 ± 2545.66 vs. 2670.62 ± 2670.04 ng/ml, p > 0.05). Serum ferritin and hepcidin levels were not correlated both in TM or TI patients (p > 0.05). However, evaluating the trend of changes in serum levels of ferritin with hepcidin showed a significant association. High serum levels of ferritin indicated high iron overload in both groups, TM and TI, which decreased after treatment with chelators. The higher hepcidin levels in TM patients in comparison to TI patients could reflect the higher iron overload in these patients. However, further cellular studies are needed to evaluate the accuracy of these tests in the assessment of iron overload.

Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61–68CrossRefPubMed

Muncie HL Jr, Campbell J (2009) Alpha and beta thalassemia. Am Fam Physician 80(4):339–344PubMed

Weatherall DJ (2008) Hemoglobinopathies worldwide: present and future. Curr Mol Med 8(7):592–599CrossRefPubMed

Samavat A, Modell B (2004) Iranian national thalassemia screening program. BMJ 329(7475):1134–1137CrossRefPubMedPubMedCentral

Fallah MS, Samavat A, Zeinali S (2009) Iranian national program for the prevention of thalassemia and prenatal diagnosis: mandatory premarital screening and legal medical abortion. Prenat Diagn 29(13):1285–1286CrossRefPubMed

Saffi M, Howard N (2015) Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Public Health Genomics 18(4):193–203CrossRefPubMed

Rund D, Rachmilewitz E (2005) β-Thalassemia. N Engl J Med 353(11):1135–1146CrossRefPubMed

Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790(7):694–701CrossRefPubMed

Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S (2016) Efficacy of Deferasirox (Exjade®) versus Osveral® in treatment of Iron overload in patients with Beta-thalassemia major in Iran; a non-randomized controlled trial. Iran J Blood Cancer 8(4):103–107

10.

Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD (2012) Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 120(5):970–977CrossRefPubMed

11.

Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S (2007) Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 109(11):5027–5035CrossRefPubMedPubMedCentral

12.

Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323–342CrossRefPubMed

13.

De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A et al (2006) Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica. 91(10):1336–1342PubMed

14.

Kaddah AM, Abdel-Salam A, Farhan MS, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. Indian J Pediatr 84(10):745–750CrossRefPubMed

15.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E (2007) Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 92(5):583–588CrossRefPubMed

16.

Britton RS, Leicester KL, Bacon BR (2002) Iron toxicity and chelation therapy. Int J Hematol 76(3):219–228CrossRefPubMed

17.

Wessling-Resnick M (2010) Iron homeostasis and the inflammatory response. Annu Rev Nutr 30:105–122CrossRefPubMedPubMedCentral

18.

Melchiori L, Gardenghi S, Rivella S (2010) beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol 2010:938640PubMedPubMedCentral

19.

Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9):1434–1443CrossRefPubMedPubMedCentral

20.

Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NLC, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101CrossRefPubMed

21.

Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, Abdollahi M, Bardestani M, Safaei S, Karimi M (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in southern Iran. Iran Red Crescent Med J 17(7):e28343PubMedPubMedCentral

22.

Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G (2006) The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 91(6):809–812PubMed

Title: Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator
Authors: Seyed Kamal Eshagh Hossaini
Mohammad reza Haeri
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keyword: Thalassemia
Published in: Journal of Hematopathology / Issue 3/2019
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-019-00363-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association between serum levels of hepcidin and ferritin in patients with thalassemia major and intermedia, the role of iron chelator

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Determining the frequency of iron overload at diagnosis in de novo acute myeloid leukemia patients with multilineage dysplasia or myelodysplasia-related changes: a case control study

Co-occurrence of CALR and MPL somatic mutations in an Indian patient with a Philadelphia-negative myeloproliferative neoplasm

Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease

Post-transplant lymphoproliferative disorder manifesting as lymphomatoid granulomatosis: report of two cases and review of the literature highlighting current challenges in pathologic classification

Comprehensive detection of chromosomal translocations in lymphoproliferative disorders by massively parallel sequencing

SOLAHP: a fledgling organization rapidly taking flight